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Background: Over the past decade, numerous reports describe the generation and increasing utility of non-small-cell
lung cancer (NSCLC) patient-derived xenografts (PDX) from tissue biopsies. While PDX have proven useful for genetic
profiling and preclinical drug testing, the requirement of a tissue biopsy limits the available patient population, particularly
those with advanced oligometastatic disease. Conversely, ‘liquid biopsies’ such as circulating tumour cells (CTCs) are
minimally invasive and easier to obtain. Here, we present a clinical case study of a NSCLC patient with advanced
metastatic disease, a never smoker whose primary tumour was EGFR and ALK wild-type. We demonstrate for the first
time, tumorigenicity of their CTCs to generate a patient CTC-derived eXplant (CDX).
Patients and methods: CTCs were enriched at diagnosis and again 2 months later during disease progression from
10 ml blood from a 48-year-old NSCLC patient and implanted into immunocompromised mice. Resultant tumours were
morphologically, immunohistochemically, and genetically compared with the donor patient’s diagnostic specimen. Mice
were treated with cisplatin and pemetrexed to assess preclinical efficacy of the chemotherapy regimen given to the donor
patient.
Results: The NSCLC CDX expressed lung lineage markers TTF1 and CK7 and was unresponsive to cisplatin and peme-
trexed. Examination of blood samples matched to that used for CDX generation revealed absence of CTCs using the
CellSearch EpCAM-dependent platform, whereas size-based CTC enrichment revealed abundant heterogeneous CTCs
of which ∼80% were mesenchymal marker vimentin positive. Molecular analysis of the CDX, mesenchymal and epithelial
CTCs revealed a common somatic mutation confirming tumour origin and showed CDX RNA and protein profiles consist-
ent with the predominantly mesenchymal phenotype.
Conclusions: This study shows that the absence of NSCLC CTCs detected by CellSearch (EpCAM+) does not preclude
CDX generation, highlighting epithelial to mesenchymal transition and the functional importance of mesenchymal CTCs in
dissemination of this disease.
Key words: non-small-cell lung cancer, circulating tumour cells, patient-derived circulating tumour cells explants (CDX),
preclinical therapeutics, epithelial to mesenchymal transition (EMT)
introduction
Interest in circulating tumour cells (CTCs) as ‘liquid biopsies’
has escalated as technical hurdles are overcome [1]. Recently, we
and others increased the scope of CTC research, demonstrating
for small-cell lung cancer (SCLC) and breast cancer, that CTCs
are tumorigenic in immunocompromised mice [2–4], creating
novel CTC-derived eXplant models (CDX). Patients whose
blood samples gave rise to CDX had >400 CTCs/7.5 ml blood
assessed using the epithelial marker-dependent (EpCAM+/pan-
cytokeratin+) CellSearch platform, yet many highly metastatic
cancers have considerably lower epithelial CTC counts. Only
32% of stage IV non-small-cell lung cancer (NSCLC) patients
had ≥2 CellSearch CTCs/7.5 ml blood [5] yet when CTC
number was defined as CD45− cells unable to pass through
8 µm filter pores, this percentage rose to 83% [6]. Filtered
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NSCLC CTCs also revealed high prevalence of vimentin expres-
sion [7, 8], consistent with mesenchymal phenotype. The
following case study supports our hypothesis that advanced
NSCLC patients’ blood (even in the absence of CellSearch
CTCs) contains tumorigenic mesenchymal CTCs of functional
importance for metastasis.
materials andmethods
patient recruitment and blood collection
A patient with histologically confirmed chemotherapy naïve NSCLC who
was referred to The Christie Hospital NHS Trust provided written informed
consent which specified their samples could be used for in vivo studies and
genetic analysis in accordance with UK regulatory requirements. The study
was prospectively approved by the NHS NorthWest 9 Research Ethical
Committee.
Blood was drawn at baseline, before administration of chemotherapy, and
again after completion of brain radiotherapy. Three 10 ml blood samples were
taken at each time point; two into EDTA vacutainers (Becton Dickinson)
for CTC enrichment before implantation into immunocompromised mice
and for ISET filtration of CTCs, and one into a CellSave vacutainer (Jansen
Diagnostics), for CellSearch CTC enumeration.
CTC enrichment before implantation into mice
Within 30 min of blood draw, a 10 ml sample of blood in an EDTA tube
was processed using the RosetteSep Human Circulating Epithelial Tumour
Cell Cocktail (Stem Cell Technology) according to the manufacturer’s
instructions and as previously described [2].
growth of CDX in immunocompromised mice
All procedures were carried out as previously described [2] in accordance
with Home Office Regulations (UK) and the UK Coordinating Committee
on Cancer Research guidelines and by locally approved protocols (Home
Office Project licence no. 40-3306). In some instances, CDX were passaged
following disaggregation using a human tumour dissociation kit (Miltenyi
Biotech) following the manufacturer’s instructions. Dead cells were removed
from the disaggregated tumour with a dead cell removal kit (Miltenyi Biotech)
following the manufacturer’s instructions. Murine cells were removed by
mixing 20 µl anti-mouse IgG2a+b microbeads (Miltenyi Biotech), 10 µl anti-
mouse MHC Class I antibody (eBioscience), and 500 µl binding buffer
(Miltenyi Biotech), incubating at 4°C for 30 min, mixing with disaggregated
tumour cells and incubating at room temperature for 15 min. Cell–bead
mixture was then applied to an LS column (Miltenyi Biotech) in a MidiMACS
separator (Miltenyi Biotech), the flow through collected, the column washed
with 4 × 3 ml binding buffer, and the flow through and wash containing the
human cells combined. Disaggregated cells were collected by centrifugation,
resuspended in 10% DMSO in fetal bovine serum (Biowest) and stored
at −80°C or in liquid nitrogen before re-implantation.
cisplatin/pemetrexed treatment of CDX
Twenty-four 10- to 12-week-old female CB-17/lcrHsd-PrkdcscidLystbg-J
(SCID-bg) mice (Harlan) were implanted with 100 000 disaggregated
CDX cells from a passage 3 CDX tumour in 100 μl of 1:1 RPMI (Life
Technologies):matrigel. As the first 20 tumours reached 200–250 mm3, the
mice were randomized by sequential assignment to cisplatin/pemetrexed
or vehicle treatment groups. Animals were treated by i.p. injection with
200 mg/kg pemetrexed (Alimta—Eli Lilly), dissolved to 20 mg/ml with 0.9%
saline solution, on day 1 followed 1 h later with 5 mg/kg cisplatin (Hospira),
supplied as a 1 mg/ml solution in 0.9% saline solution, or corresponding
vehicle only. Tumour volume was monitored blinded to treatment group
three times a week until tumour reached 1000 mm3.
immunohistochemistry
TTF-1 and CK7 IHC was carried out on formalin-fixed, paraffin-embedded
tissue 4 μm sections using anti-TTF-1 (mouse, 8GTG3/1, 1:200, Dako,
Carpinteria, CA, USA) and anti-CK7 (mouse, OV-TL 12/30, 1:1000, Dako).
Antibody incubation and detection were carried out at 37°C on a Menarini
intelliPATH FLX (A. Menarini Diagnostics, UK) using Menarini’s reagent
buffer and detection kits unless otherwise noted. Antigen retrieval was
carried out in a pressure cooker in citrate buffer pH6 for 2 min at 123°C.
Pan-CK, CD44 and vimentin IHC was carried out on formalin-fixed, paraffin-
embedded tissue 4 μm sections using anti pan-cytokeratin antibody (mouse,
M3515, 1:60, ER1 20 min Dako), anti CD44 (mouse, DF1485, 1:100, ER2
10 min, Dako) and anti-Vimentin (mouse, V9, CC1 32 min, Roche). Pan-CK
and CD44 staining was carried out on the LEICA Bond Max Platform and
Vimentin staining on the Ventana Discovery Ultra platform (Roche).
Appropriate positive, negative and isotype controls were included with the
study sections (not shown). Digital images of whole-tissue sections acquired
using a Leica SCN400 histology scanner (Leica Microsystems).
CellSearch CTC enumeration
Blood drawn into a CellSave tube was analysed for the presence of CTCs
using the CellSearch platform and CTC kit (Jansen Diagnostics) according
to the manufacturer’s instructions and as previously described [7]. A cell was
defined as a CTC if it expressed EpCAM and CK, was >4 µm in diameter,
had an intact DAPI-stained nuclei, and did not express CD45.
ISET CTC enrichment, immunofluorescence
staining, and epithelial/mesenchymal phenotype
scoring
Ten millilitres of blood drawn into an EDTA tube were stored at 4°C and
processed by ISET filtration (Rarecells) within 4 h of collection according to
the manufacturer’s instructions and as previously described [6] and stored at
−20°C. ISET-filtered CTCs were stained by multi-parameter immunofluor-
escence using antibodies against CD45 (leukocyte marker), pan-cytokeratins
(epithelial cell marker), vimentin (mesenchymal cell marker), and VE-
cadherin (CD144, endothelial cell marker). Filters were rehydrated (1 min in
PBS + 0.02% Tween-20), permeabilized (0.2% Triton X-100 for 10 min), and
washed for 1 min in PBS + 0.02% Tween-20. Antibody incubations were as
follows: 10% goat serum block (Dako X0907) for 30 min; a cocktail (80 µl)
of two primary antibodies, unconjugated anti-CD45 (1:400 of 0.4 mg/ml,
Rabbit, Abcam AB10559), and unconjugated anti-VE-cadherin (1:200 of
0.5 mg/ml, Mouse, eBioscience 14-1449-82), for 1 h; a cocktail (80 µl) of two
fluorescent secondary antibodies, Goat anti-mouse AF555 (1:500 of 2 mg/ml
Invitrogen A21422) and Goat anti-rabbit DY549 (1:500 of 1 mg/ml Thermo
Scientific35 558) for 1 h; a cocktail (80 µl) of two conjugated primary anti-
bodies, anti-vimentin 647 (1:50 of 0.05 mg/ml Santa Cruz sc-6260) and anti-
CK FITC (1:100 of 3 mg/ml, Sigma F3418, clone C11 against CKs 4, 5, 6, 8,
10, 13, and 18) for 1 h; and 80 µl of DAPI (1:10 000 of 5 mg/ml, Invitrogen
D3571) for 5 min. The filters were washed twice in PBST between incuba-
tions then twice in double distilled water before mounting with ProLong
Gold anti-fade (Invitrogen P36934). Slides were left overnight at room tem-
perature to dry and imaged with a MIRAX automated slide scanner
(3DHistech, Budapest, Hungary). Images were reviewed with 3DHistech
panoramic viewing software (Version 1.15.1.10). This assay detects CD45
and VE-cadherin positive cells (leucocytes and endothelial cells) with the
same fluorescence emission (both labelled with fluorophores with red
spectral emission). Therefore, tumour cells in this assay were at the outset of
the study defined as having neither marker (i.e. CTCs are defined as
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cytokeratin and/or vimentin positive and CD45 and VE-cadherin negative).
Expression of vimentin and/or cytokeratins on filtered cells was evaluated by
analysts with extensive experience in CTC research.
whole-exome sequencing
The CDX tumours were disaggregated using a sterile scalpel and gDNA iso-
lated using the QiaAmp DNA Mini kit (Qiagen). DNA libraries were then
generated from 750 ng gDNA in the NEBNext Ultra DNA Library kit (NEB)
and enriched for exome-specific sequences using the SureSelect Human All
Exon V5 kit (Agilent) following the manufacturer’s instructions. Resulting
libraries were then sequenced on an Illumina HiSeq2500 instrument using
the TruSeq PE Cluster Kit V3 and TruSeq SBSv3 chemistry. Bioinformatic
analysis was carried out as previously described [2].
single-cell laser capture microdissection
A spot of an ISET filter stained for multiple markers as described above was
washed with water, dried and mounted on a membrane-free LCM metal-
framed slide. Cells were visualized on a Leica LMD6000 LCM microscope
(Leica Microsystems) at 60× magnification and epithelial, mesenchymal, and
mixed phenotype CTCs and leucocytes/endothelial cells were identified. Cells
were dissected under direct immunofluorescent microscopic visualization and
dropped directly into the lid of a 0.2 ml collection tube. Twelve single CTCs,
four pools of two out of three CTCs eight single leucocytes/endothelial cells,
and four pools of three out of four leucocytes/endothelial cells were micro-
dissected and used for subsequent downstream analysis. The cells selected via
fluorescence attributed to CD45 or VE-Cadherin (CD44) were small cells and
more likely to be leucocytes than endothelial cells.
Sanger sequencing
Captured cells were centrifuged at 15 000g for 10 min. DNA was extracted
and amplified with a Picoplex Whole Genome Amplification kit (Rubicon)
according to the manufacturer’s instructions. Products of DNA amplifica-
tion were checked on an agarose gel 1.5%, purified using the High Pure PCR
Kit (Roche) and quantified using Qubit fluorometer (Life Technologies).
Sanger sequencing assays to detect 18 somatic mutations were tested on the
amplified DNA, but due to technical inefficiencies, only the assay to detect
a G340A mutation in PACRG proving fit for purpose. In brief, a portion
of the PACRG gene containing the mutated locus was amplified using
primers PACRG-F1 (50-GCCCGAATGCTGTTTTCACA) and PACRG-R1
(50-GGTTGTCTGGCCTCCTAAGT) with PCR cycling conditions of 98°C
for 20 s, 59°C for 30 s, 72°C for 30 s for 33 cycles using TaKaRa Ex Taq HS
DNA Polymerase (TaKaRa Bio). The resulting PCR product was then puri-
fied using QIAquick PCR Purification Kit (Qiagen) and directly sequenced.
RNAseq
CDX-derived tumour tissue fragments were collected from autopsied
animals into RNAlater (Sigma) and stored at −80°C. Tumours were manual-
ly disaggregated using a sterile scalpel, before undergoing RNA extraction by
miRNeasy mini kit (Qiagen) following the manufacturer’s instructions.
Next-generation sequencing libraries were generated by SureSelect Poly A kit
(Aligent), before undergoing 150 bp Paired End sequencing on a NextSeq
500 sequencer (Illumina). The RNASeq data were aligned to Human
GRCh38 and Mouse GRCm38 assembly using Mapsplice (Version 2.1.6).
Reads aligning to the mouse genome were removed from the set of human-
aligned reads. Filtered reads were then used to generate counts data using
Rsubread (Version 1.16.1) with Ensembl version 77 GTF file. Counts were
converted into Reads Per Kilobase per Million mapped (RPKM), which were
then used for expression level quantification of the genes.
results
A 48-year-old male was recruited through an ongoing, ethically
approved translational lung cancer research programme.
Diagnostic computer tomography identified a T1aN2M1b stage
tumour (TNM 7th edition [9]) with a 2 cm right lung primary
and metastases to brain, bone, kidney, mediastinal, and para-
aortic lymph nodes. His diagnostic biopsy (a para-aortic lymph
node) contained sheets of polygonal poorly differentiated
adenocarcinoma cells that were positive for lung markers,
thyroid transcription factor (TTF1), and cytokeratin7 (CK7)
and negative for p40 (squamous marker), CD56, chromogranin
A, synaptophysin (neuroendocrine markers), and CK20 (gastro-
intestinal marker). Molecular testing demonstrated wild-type
EGFR and was negative for ALK gene rearrangement. The
patient commenced on chemotherapy with cisplatin and peme-
trexed but discontinued after one cycle with deterioration of his
general condition due to brain metastases. Despite administra-
tion of whole-brain radiotherapy (20 Gy, 5 fractions), the
patient continued to deteriorate with progressive neurological
symptoms and died 2 months following initial diagnosis. Three
blood samples were drawn before chemotherapy (baseline) and
after brain radiotherapy. After blood cell depletion from one
sample, the CTC-enriched fraction was implanted into an im-
munocompromised mouse within 2 h of blood draw to attempt
CDX generation. The other samples were processed for CTC
analysis using CellSearch and ISET filtration.
No CDX was derived at baseline, but post-radiotherapy CTCs
gave rise to a palpable tumour 95 days after implantation; CDX
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Figure 1. NSCLC CDX growth, histology and response to therapy. (A)
Mouse bearing a passage 2 CDX derived from CTCs enriched from an
NSCLC patient (scale bar, 1 cm) and the resected tumour (scale bar, 5 mm).
(B) Size of CDX tumour shown in A versus time post-implantation. (C)
Patient biopsy and CDX shown in A stained for H&E, TTF1, and CK7 (scale
bar, 50 µm). (D) Twenty-four SCID-bg mice were implanted with 100 000
disaggregated cells from a passage 4 CDX. When tumours reached ∼200
mm3, they were randomly assigned to a vehicle control group (n = 10) or 5
mg/kg cisplatin bolus, 200 mg/kg pemetrexed bolus-treated group (n = 10).
Tumour volume was monitored two to three times a week.
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fragments implanted into additional mice resulted in palpable
tumours ∼30 days later (Figure 1A and B). The CDX resembled
a poorly differentiated lung adenocarcinoma, comprising diffuse
sheets of large polygonal cells with abundant eosinophilic cyto-
plasm, vesicular chromatin, and enlarged nucleoli (Figure 1C).
Both biopsy and CDX expressed TTF1. CK7 was expressed in
∼10% versus 100% CDX cells versus biopsy, suggesting a less
epithelial CDX phenotype (Figure 1C). The CDX, when treated
with cisplatin and pemetrexed (the same chemotherapy doublet
as the patient), was resistant to treatment (no impact on tumour
growth) suggesting that had progressive neurological symptoms
not prevented the patient’s continuation of chemotherapy, treat-
ment may still not have improved the outcome (Figure 1D).
CellSearch analysis detected four EpCAM+/CK+ CTCs/7.5 ml
blood at baseline and zero CTCs post-radiotherapy. Multi-
parameter immunofluorescence on the post-radiotherapy filtered
blood sample blood revealed >150 CTCs (CD45−/CD144−)
cells/ml comprising epithelial CK+/vimentin− (23%), mesenchy-
mal CK−/vimentin+ (30%), and mixed phenotype CK+/vimen-
tin+ (47%) CTCs; circulating tumour microemboli containing
cells of all three phenotypes were also detected (Figure 2A and B).
CDX whole-exome sequencing (supplementary Table 1, available
at Annals of Oncology online) revealed somatic mutations in 247
genes, including TP53 and KEAP1, commonly mutated in
NSCLC. To confirm tumour origin of filtered CTCs, we sought
common mutations in tumour biopsy, CDX, and cells designated
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Figure 2. Epithelial/mesenchymal nature of patient CTCs and CDX. CTCs were enriched via ISET filtration from a parallel blood sample to that which gener-
ated the CDX. The ISET filter was stained for pan-CK (green), vimentin (blue), CD45 and CD144 (pink), and DAPI (white). (A) Representative images and
(B) quantitation of cells classed as epithelial, mixed epithelial/mesenchymal (E/M), and mesenchymal. Also shown is a circulating tumour microemboli (CTM)
containing cells of all three phenotypes. *Leucocyte or endothelial cell; scale bar, 10 µm. Quantitation carried out by two independent scorers on two ISET
spots, each counting >150 CTCs per spot. Error bars, SEM. (C) Single cells from the ISET filter shown in A classed as a leucocyte/endothelial cell, epithelial
CTC, mixed E/M CTC, or a mesenchymal CTC were captured by laser capture microdissection. The PACRG locus, shown by WES to be mutated in the CDX,
was Sanger sequenced in DNA extracted from the captured CTCs and green fluorescent cells (leucocytes or endothelial cells), from the patients PBMCs (germ-
line sample), from their primary tumour biopsy and from the passage 2 CDX shown in Figure 1A–C. Highlighted base represents the mutated base. (D)
RNAseq was carried out on passage 2 NSCLC CDX tumours and passage 3 CDX from two SCLC CDX models. Expression of EPCAM, KRT8, VIM, S100A4,
CD44, and CD24 is displayed as RPKM values. Data represent mean of three independent tumours ± SEM. *P < 0.05; ***P < 0.001 according to two-tailed
unpaired t-test. (E) Tumours analysed in D were stained for expression of pan-CK, vimentin, and CD44 (scale bar, 50 µm).
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as CTCs (retrieved by laser capture microdissection for genomic
DNA extraction and amplification) not present in leucocytes/
endothelial cells. Confirmation of CTC tumour origin (by
Sanger sequencing) was demonstrated by the absence of a
G340A mutation in PACRG in germline DNA present in
primary tumour, CDX, and single epithelial, mesenchymal, and
mixed phenotype CTCs (Figure 2C). Expression of genes asso-
ciated with epithelial or mesenchymal phenotypes [10, 11] was
evaluated after RNAseq of passage 3 CDX (Figure 2D, supple-
mentary Table 2, available at Annals of Oncology online).
Consistent with a mesenchymal phenotype, the NSCLC CDX
expressed low levels of epithelial genes EPCAM and KRT8, high
levels of mesenchymal genes vimentin and S100A4 [11], and a
high ratio of CD44:CD24 [10]. The NSCLC CDX expressed
low protein levels of pan-CK and high levels of vimentin and
CD44 (Figure 2E). These RNA and protein profiles contrasted
with a SCLC CDX from a donor patient with 458 EpCAM+/CK+
CTCs/7.5 ml blood [2] which displayed a strong epithelial
phenotype.
discussion
We report for the first time, NSCLC circulating cells with
tumour initiating potential and CDX generation from a patient
without detectable EpCAM+/CK+ CTCs [2, 3]. These data high-
light the potential for CDX models from metastatic cancers with
low prevalence of CellSearch CTCs (e.g. pancreatic cancer) and
where biopsy material is often scarce, resulting in insufficient
material for comprehensive molecular profiling. Our data also
denote the importance of non-epitope-dependent technologies
for CTC enrichment [12, 13]. While we do not formally distin-
guish dynamic EMT from epithelial and mesenchymal cell co-
operation during haematological dissemination, these data do
highlight a functional importance of mesenchymal CTCs and
need for treatment strategies that target them (e.g. AXL inhibi-
tors) [14]. The persistent, predominant mesenchymal pheno-
type of the established CDX may also suggest that mesenchymal
to epithelial transition (MET) [11] may not always reverse after
NSCLC cell dissemination.
In this case, the patient died to his disease 1 day after the
blood draw that generated the CDX. This exemplifies how CDX
can represent end of life disease models and the pressing need
to better understand progressive disease biology and therapeutic
options for advanced patients. The CDX approach contrasts
with the majority of patient-derived xenografts (PDX) generated
from resected tissue during surgery with curative intent [15].
CDX can be generated from patients with little deviation from
routine practice and this study demonstrates the potential for
this approach to be applied to cancers with few CellSearch de-
tectable CTCs. It remains to be determined how frequently
CDX could be generated from NSCLC patients with no/few
CellSearch detectable CTCs. At the time of submission, we had
implanted 34 samples enriched for CTC from NSCLC patients
into mice with no further CDX yet detectable. However, the
time from CTC implant to CDX detection can be over 6
months, so this dataset needs to mature before conclusions
regarding CDX ‘take rate’ can be drawn. This time frame pre-
cludes the use of NSCLC CDX as ‘avatars’ in co-clinical trials to
direct patient treatment. However, if CDX can be routinely
generated from NSCLC patients, they have the potential to
provide paired models from the same patient at baseline and at
progression to study drug resistance mechanisms. We suggest
that CDX would represent optimal preclinical models to test
novel therapeutic regimens before commencing early clinical
trials, as they can be generated from the cohort of patients better
representing those at trial entry.
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